厄贝沙坦对病态窦房结综合征患者双腔起搏后阵发性心房颤动的影响被引量：2

Influence of irbesartan on paroxysmal atrial fibrillation after dual-chamber pacing in patients with sick sinus syndrome

下载PDF

导出

摘要目的观察厄贝沙坦对病态窦房结综合征(SSS)患者双腔起搏后阵发性心房颤动(Af)的影响。方法入选84例双腔起搏术后1个月仍有阵发性Af的SSS患者,随机分为治疗组(n=42)和对照组(n=42)。在治疗基础疾病的基础上,治疗组给予厄贝沙坦150mg/d,对照组不予血管紧张素转化酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB)。随诊1年,观察左房内径、血清高敏C反应蛋白(hsCRP)水平、Af发作次数(次/d)及Af负荷(h/d)等。结果起搏器置入术后1年,治疗组左房内径、hsCRP、Af发作次数及Af负荷显著低于对照组,分别为[(3.91±0.22)cmvs.(4.48±0.46)cm],[(3.42±1.63)mg/Lvs.(5.23±2.11)mg/L],[(3.15±2.83)次/dvs.(6.46±4.28)次/d],[(0.46±0.28)h/dvs.(0.69±0.32)h/d](P均<0.05);同时显著低于同组厄贝沙坦用药前水平(P均<0.05);对照组上述指标厄贝沙坦治疗前后变化无显著性差异(P>0.05)。结论厄贝沙坦可减轻SSS双腔起搏后心房重构、降低hsCRP水平,减少阵发性Af的发生。 Objective To observe the influence of irbesartan on paroxysmal atrial fibrillation（Af） after dual-chamber pacing in the patients with sick sinus syndrome（SSS）.Methods The SSS patients（n=84） with paroxysmal Af one month after dual-chamber pacing were chosen and randomly divided into the treatment group（n=42） and control group（n=42）.On the base of treating basic diseases,the treatment group was given irbesartan（150 mg/d） and the control group was not given angiotensin-converting enzyme inhibitor（ACEI） or angiotensin II receptor blocker（ARB）.After follow-up for one year,the internal diameter of left atrium,the serum level of high sensitivity C-reactive protein（hs-CRP）,times of Af onset（times/d） and Af burden（h/d） were observed.Results One year after pace maker implanted,the internal diameter of left atrium,hs-CRP,times of Af onset and Af burden were all significantly lower in the treatment group than those in the control group,respectively,[（3.91±0.22） cm vs.（4.48±0.46） cm],[（3.42±1.63） mg/L vs.（5.23±2.11） mg/L],[（3.15±2.83） times/d vs.（6.46±4.28） times/d],[（0.46±0.28） h/d vs.（0.69±0.32） h/d],（all P0.05）.All above indexes were significantly lower in the treatment group after treatment than those before the treatment（all P0.05）,and in the control group,there was no significant difference（P0.05）.Conclusion Irbesartan can alleviate atrial remodeling,reduce hs-CRP level and decrease the onset of paroxysmal Af after Dual-chamber pacing in SSS patients.

作者郭艾武崔勤范杰陶卫萍仇庆华王蓬波马宏华童小燕

机构地区扬州大学第四临床医学院南通瑞慈医院心脏中心

出处《中国循证心血管医学杂志》 2011年第5期368-370,共3页 Chinese Journal of Evidence-Based Cardiovascular Medicine

关键词心房颤动病态窦房结综合征双腔起搏厄贝沙坦 Atrial fibrillation Sick sinus syndrome Dual-chamber pacing Irbesartan

分类号 R541.74 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1Wijffels MC,Kirchhof CJ,Dorland R,et al.Atrial fibrillation begets atrial fibrillation.A study in awake chronically instrumented goats[J].Circulation,1995,92(3):1954-1968.
2Gillis AM,MorcK M.Atrial fibrillation following DDDR pacemaker implantation[J].J Cardiovasc Electmphysiol,2002,13(6):542-543.
3Mandava A,Mittal S.Clinical significance of pacemaker-detected atrial high-rate episodes[J].Curr Opin Cardiol,2008,23(1):60-62.
4Cheung JW,Keating Ill,Stein KM,et al.Newly detected atrial fibrillation following dual chamber pacemaker implantation[J].J Cardiovasc Electrophysiol,2006,17(12):323-324.
5李恭,任澎.心房颤动与炎症及肾素-血管紧张素系统关系的研究进展[J].心血管病学进展,2010,31(5):748-751. 被引量：2
6Euler DE,Friedman PA.Atrial arrhythmia burden as an endpoint in clinical trial:Is it the best surrogate?Lessons from a muhicenter defibrillatortrial[J].CEPR,2003,7(4):355-356.
7Chung MK,Martin DO,Sprecher D,et al.C-reactive protein elevation in patients with atrial arrhythmias:inflammatory mechanisms and persistence of atrial fibrillation[J].Circulation,2001,104(24):2886-2891.
8Healey JS,Baranchuk A,Crystal E,et al.Prevention of atrial fibrillation withangiotensin-converting enzyme inhibitors and angiotensin receptor blockers:ameta-analysis[J].J Am Coil Cardiol,2005,45(2):1832-1839.
9方昱,严激.胺碘酮与厄贝沙坦联用对病态窦房结综合征人工心脏起搏后的疗效[J].中国临床保健杂志,2008,11(1):25-26. 被引量：4

二级参考文献25

1[1]Mast EG,Van Hemel NM,Bakema L,et al.Is chronic atrial stimulation a reliable method for single chanmber pacing in sick sinus syndrome?[J].PACE,1986,38 (9):1127-1154.
2[2]Satoh T,Zipes DP.Unequal atrial stretch in dog increases dispersionof refractoriness conductive to developing atrial fibrillation[J].J Cardiovasc Electrophysiol,1996,7 (4):833-842.
3[3]Goette A,Honeycuttc,Iangbergjj,et al.Eletrical remodeling in atrial fibrillation; time course and mechisms[J].Circulation,1996,94 (2):2968-2974.
4[4]Goette A,Staack T,Rockcn C,et al.Increased expression of extracellular signal regulated kinase and angiotensinconverting enzyme in human atrial during atrial fibrillation[J].J Am Coll Cardiol,2003,5 (11):1669-1677.
5[5]Nakashima H,Kumagai K,Urata H,et al.Angiotensin Ⅱ antagonist prevents electrical remodeling in atrial fibrillation[J].Circulation,2000,101 (22):2612-2617.
6Bruins P,te Velthuis H,Yazdanbakhsh AP,et al.Activation of the complement system during and after cardiopulmonary bypass surgery:postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia[J].Circulation,1997,96:3542-3543.
7Lo B,Fijinheer R,Nierich AP,et al.C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization[J].Ann Thorac Surg,2005,79:1530-1535.
8Chung MK,Martin DO,Sprecher D,et al.C-reactive protein elevation in patients with atrial arrhythmias:inflammatory mechanisms and persistence of atrial fibrillation[J].Circulation,2001,104(24):2886-2891.
9Sata N,Hamada N,Horinouchi T,et al.C-reactive protein and atrial fibrillation is inflammation a consequence or a cause of atrial fibrillation[J] ?Jpn Heart J,2004,45:441-445.
10Dernellis J,Panaretou M.Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation[J].Eur Heart J,2004,25(8):1100-1107.